Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127532591 | 12753259 | 1 | I | 20100604 | 20100701 | 20160916 | 20160916 | EXP | US-ROCHE-714616 | ROCHE | 67.67 | YR | M | Y | 94.40000 | KG | 20160916 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127532591 | 12753259 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 28 DAYS, OVER 30-90 MINS ON DAYS 1 AND 15, LAST DOSE PRIOR TO SAE 14 MAY 2010 | 125085 | 1888 | MG | ||||||||
| 127532591 | 12753259 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | 125085 | 944 | MG | |||||||||
| 127532591 | 12753259 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | 125085 | 1628 | MG | |||||||||
| 127532591 | 12753259 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | 125085 | 814 | MG | |||||||||
| 127532591 | 12753259 | 5 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | DAY 1,8,15,22 LAST DOSE PRIOR TO SAE ON 21/MAY/ 2010 | 0 | 100 | MG | ||||||||
| 127532591 | 12753259 | 6 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | 0 | 40 | MG | |||||||||
| 127532591 | 12753259 | 7 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | 0 | 60 | MG | |||||||||
| 127532591 | 12753259 | 8 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | 0 | 30 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127532591 | 12753259 | 1 | Carcinoid tumour |
| 127532591 | 12753259 | 5 | Carcinoid tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127532591 | 12753259 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127532591 | 12753259 | Blood bilirubin increased | |
| 127532591 | 12753259 | Nausea | |
| 127532591 | 12753259 | Small intestinal obstruction | |
| 127532591 | 12753259 | Vomiting | |
| 127532591 | 12753259 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |